{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzp1q1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzp1q1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/18\\\/33\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;14\\\/18\\\/33\u0022}],\u0022ac\u0022:{\u0022spmdc;14\\\/18\\\/33\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;14\\\/18\\\/33\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EAccurate blood pressure (BP) measurement is essential to reduce cardiovascular risk and accurately identify treatment resistant hypertension (RH). Home BP monitoring and 24-hour ambulatory BP monitoring are complementary to office BP measurement. This article reviews the recommendations for their use by the European Society of Hypertension and European Society of Cardiology Hypertension Guidelines [Mancia G et al. \u003Cem\u003EJ Hypertens\u003C\/em\u003E 2013], as well as discusses updates in the treatment of RH.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EInterventional Techniques \u0026amp; Devices Renal Disease\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EHypertensive Disease\u003C\/li\u003E\u003C\/ul\u003E\u003Cul class=\u0022kwd-group clinical-trial\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EInterventional Techniques \u0026amp; Devices\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ECardiology \u0026amp; Cardiovascular Medicine\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ERenal Disease\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EHypertensive Disease\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EAccurate blood pressure (BP) measurement is essential to reduce cardiovascular (CV) risk and accurately identify treatment resistant hypertension (RH), said Gianfranco Parati, MD, University of Milano-Bicocca, Milan, Italy. Home BP monitoring (HBPM) and 24-hour ambulatory BP monitoring (ABPM) are complementary to office BP measurement (OBPM). Dr. Parati reviewed the recommendations for their use by the European Society of Hypertension (ESH) and European Society of Cardiology (ESC) Hypertension Guidelines [Mancia G et al. \u003Cem\u003EJ Hypertens\u003C\/em\u003E 2013].\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EOBPM is recommended for screening and diagnosing hypertension (\u22652 measurements at \u22652 visits) and is currently used for risk stratification. HBPM and ABPM are recommended to confirm the diagnosis of hypertension, distinguish the phenotype (eg, white coat hypertension [WCH], masked hypertension [MH], sustained hypertension, and true normotension); detect hypotensive episodes, and maximize CV risk prediction. The BP levels to diagnose hypertension with each approach are shown in \u003Ca id=\u0022xref-table-wrap-1-1\u0022 class=\u0022xref-table\u0022 href=\u0022#T1\u0022\u003ETable 1\u003C\/a\u003E.\u003C\/p\u003E\u003Cdiv id=\u0022T1\u0022 class=\u0022table pos-float\u0022\u003E\u003Cdiv class=\u0022table-inline\u0022\u003E\u003Cdiv class=\u0022callout\u0022\u003E\u003Cspan\u003EView this table:\u003C\/span\u003E\u003Cul class=\u0022callout-links\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022\/\u0022 class=\u0022table-expand-inline\u0022 data-table-url=\u0022\/highwire\/markup\/14640\/expansion?postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed\u0026amp;table-expand-inline=1\u0022 html=\u00221\u0022 fragment=\u0022#\u0022 external=\u00221\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView inline\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022\/highwire\/markup\/14640\/expansion?width=1000\u0026amp;height=500\u0026amp;iframe=true\u0026amp;postprocessors=highwire_figures%2Chighwire_math%2Chighwire_inline_linked_media\u0022 class=\u0022colorbox colorbox-load table-expand-popup\u0022 rel=\u0022gallery-fragment-tables\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView popup\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/14640\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cdiv class=\u0022table-caption\u0022\u003E\u003Cspan class=\u0022table-label\u0022\u003ETable 1.\u003C\/span\u003E \n            \u003Cp id=\u0022p-4\u0022 class=\u0022first-child\u0022\u003EDefinitions of Hypertension Using Office, Ambulatory, and Home Measurements\u003C\/p\u003E\n         \u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cp id=\u0022p-6\u0022\u003EThe ESH Practice Guidelines for HBPM, developed with general practitioners, provides a concise course of action for its use and data to support its better risk prediction compared with OBPM in a general hypertensive population, in the elderly, and in patients with chronic kidney disease [Parati G et al. \u003Cem\u003EJ Human Hypertens\u003C\/em\u003E 2010].\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EImportant prognostic information is also obtained with HBPM by assessing changes in BP, such as day-to-day BP variability. Data from Japan showed that patients with the highest level of day-to-day BP variability on HBPM had the highest rate of CV mortality [Kikuya M et al. \u003Cem\u003EHypertension\u003C\/em\u003E 2008]\u003Cem\u003E.\u003C\/em\u003E\n      \u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EHBPM is useful as a tool to improve patient adherence by involving patients in the monitoring and management of their condition, especially when coupled with web-based systems that are interactive. The TeleBPCare study showed a significant improvement in daytime BP control in patients with the BP telemonitoring system (HBPM group) compared with OBPM (62% vs 50%; p\u0026lt;0.05) and less frequent changes in treatment (9% vs 14%; p\u0026lt;0.05), as well as a higher quality of life and lower costs [Parati G et al. \u003Cem\u003EJ Hypertens\u003C\/em\u003E 2009].\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EAccording to the ESH\/ESC Guidelines, ABPM has an even greater prognostic significance than HBPM, with a better correlation with organ damage, a stronger relation with clinical outcomes, and better predictive values [Mancia G et al. \u003Cem\u003EJ Hypertens\u003C\/em\u003E 2013]. ABPM is also used to distinguish among hypertension phenotypes, identify other conditions such as obstructive sleep apnea (OSA), assess responses to treatment, and assess the impact of hypertension on CV targets.\u003C\/p\u003E\u003Cp id=\u0022p-10\u0022\u003EThe ESH Position Paper on ABPM, which complements the ESH\/ESC Hypertension Guidelines, also provides detailed instructions for its use [O\u0027Brien E et al. \u003Cem\u003EJ Hypertens\u003C\/em\u003E 2013]. The updated document provides even greater detail in terms of its clinical use, including a thorough review of ABPM to identify WCH, MH, and nocturnal hypertension, and its use in research [Parati G et al. \u003Cem\u003EJ Hypertens\u003C\/em\u003E 2014].\u003C\/p\u003E\u003Cp id=\u0022p-11\u0022\u003EIn patients with OSA, the first sign of hypertension may be the identification of a \u201cnondipper\u201d pattern at night with ABPM [O\u0027Brien E et al. \u003Cem\u003EJ Hypertens\u003C\/em\u003E 2013]. A consensus statement from the European Respiratory Society and the ESH for the management of patients with OSA and hypertension recommends the use of ABPM to diagnose hypertension and manage patients to ensure adequate 24-hour protection.\u003C\/p\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003ETREATMENT OF RESISTANT HYPERTENSION\u003C\/h2\u003E\n         \u003Cp id=\u0022p-12\u0022\u003ETrue RH is rather uncommon, according to Sverre E. Kjeldsen, MD, Oslo University Hospital, Oslo, Norway. Poor adherence to prescribed drug treatment is the number one cause of apparent RH and must be ruled out for accurate diagnosis, along with evaluating the adequacy of the treatment regimen and other factors.\u003C\/p\u003E\n         \u003Cp id=\u0022p-13\u0022\u003EFour randomized controlled trials, including one large sham-controlled trial of renal denervation (RDN), have shown minimal benefit. Ongoing research of RDN may eventually demonstrate utility in selected patients. In theory, RDN is an attractive approach to treating true RH, although the balance of the evidence does not currently support its use, stated Prof. Kjeldsen.\u003C\/p\u003E\n         \u003Cp id=\u0022p-14\u0022\u003EThe open-label SYMPLICITY HTN-2 study showed a significant reduction in systolic and diastolic BP (SBP; DBP) at Months 1, 3, and 6 (p\u22640.005 for each time point vs sham control) [SYMPLICITY HTN-2 Investigators. \u003Cem\u003ELancet\u003C\/em\u003E 2010]. However, Prof. Kjeldsen stated that the lack of blinding and 24-hour ABPM are issues with this trial, along with regression to the mean, the Hawthorne effect, in which participant performance is enhanced because of increased attention, and the placebo effect.\u003C\/p\u003E\n         \u003Cp id=\u0022p-15\u0022\u003EThe first prospective, randomized study of RDN versus clinical drug adjustment, the OsloRDN study, found a small non-significant reduction in SBP using OPBM at Months 3 and 6, and the BP was found to be normalized in the drug treatment arm [Fadl Elmula EE et al. \u003Cem\u003EHypertension\u003C\/em\u003E 2014]. Using daytime ABPM, there were small changes only in SBP or DBP at Months 3 and 6. This finding fits well with the placebo effect of RDN, stated Prof. Kjeldsen, and showed that the strategy of adjusting drug treatment was superior to RDN.\u003C\/p\u003E\n         \u003Cp id=\u0022p-16\u0022\u003EThe Oslo RDN study used the same inclusion criteria as the SYMPLICITY HTN-2, plus the witnessed intake of antihypertensive medications by patients prior to ABPM. Notably, after the witnessed intake of medication, 14 of 65 screened patients had controlled BP [Fadl Elmula EE et al. \u003Cem\u003EHypertension\u003C\/em\u003E 2014], whereas only 6 of 18 patients qualified as having true RH in an earlier open study [Fadl Elmula EE et al. \u003Cem\u003EHypertension\u003C\/em\u003E 2013]. At baseline, patients who qualified were taking an average of 5 antihypertensive drugs.\u003C\/p\u003E\n         \u003Cp id=\u0022p-17\u0022\u003EThe SYMPLICITY HTN-3 was the first randomized, sham-controlled study of RDN and failed to show a significant benefit in the primary endpoint of office SBP (\u201314.1 mmHg vs \u221211.7 mmHg, respectively; p\u0026lt;0.001 for both) and no significant difference at Month 6 from baseline (\u20132.39 mm Hg; 95% CI, \u22126.89 to 2.12; p=0.26) [Bhatt DL et al. \u003Cem\u003EN Engl J Med\u003C\/em\u003E 2014]. There was also no difference between groups in the secondary efficacy endpoint of change in 24-hour systolic ABPM (\u20131.96 mmHg; 95% CI, \u22124.97 to 1.06; p=0.98).\u003C\/p\u003E\n         \u003Cp id=\u0022p-18\u0022\u003EThe BEAUTY study investigated the use of an integrated, noninvasive monitoring system that applies a predefined algorithm of drug selection in reducing ambulatory-based SBP. The system showed that BP control was achieved early and correlated with improvement in hemodynamics at Month 6 and that the system was associated with improved tolerability of antihypertensive agents [Parati G et al. \u003Cem\u003EESH\u003C\/em\u003E 2014]. Selected patients with volume overload required a high-dose thiazide diuretic.\u003C\/p\u003E\n         \u003Cp id=\u0022p-19\u0022\u003EBaroreceptor activating therapy with an implanted device has been shown to be effective, with a mean BP reduction of 35\/16 mmHg and 55% of long-term responders achieving goal BP levels [Bakris GL et al. \u003Cem\u003EJ Am Soc Hypertens\u003C\/em\u003E 2012]. Prof. Kjeldsen anticipates that it will be increasingly used in the United States and Europe.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2014 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/14\/18\/33.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzp1q1\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_tables.js?nzp1q1\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}